Novel upstream approaches to prevent atrial fibrillation perpetuation

Cardiology Clinics

Volumn 32, Issue 4, 2014, Pages 637-650

  Jalife, José ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Atrial fibrillation; Fibrosis; Myocytes; Myofibroblast

Indexed keywords

ACETYLCYSTEINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ASCORBIC ACID; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GALECTIN 3; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MINERALOCORTICOID ANTAGONIST; REACTIVE OXYGEN METABOLITE;

CORONARY ARTERY BYPASS SURGERY; DISEASE MODEL; HEART ATRIUM FIBRILLATION; HEART ATRIUM REMODELING; HEART EXCITATION; HEART MUSCLE FIBROSIS; HUMAN; INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PAROXYSMAL HEART ATRIUM FIBRILLATION; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY VEIN ISOLATION; RADIOFREQUENCY ABLATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; ATRIAL FIBRILLATION; ELECTROPHYSIOLOGY; HEART ATRIUM; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PREVENTIVE HEALTH SERVICE;

ATRIAL FIBRILLATION; ATRIAL REMODELING; ELECTROPHYSIOLOGICAL PHENOMENA; HEART ATRIA; HUMANS; OXIDATIVE STRESS; PREVENTIVE HEALTH SERVICES; RENIN-ANGIOTENSIN SYSTEM;

EID: 84927509427     PISSN: 07338651     EISSN: 15582264     Source Type: Journal    
DOI: 10.1016/j.ccl.2014.07.004     Document Type: Review

References (96)

1. Savelieva I., Camm J. Update on atrial fibrillation: part I. Clin Cardiol 2008, 31:55-62.
2. Majeed A., Moser K., Carroll K. Trends in the prevalence and management of atrial fibrillation in general practice in England and Wales, 1994-1998: analysis of data from the general practice research database. Heart 2001, 86:284-288.
3. Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 1991, 22:983-988.
4. Feinberg W.M., Blackshear J.L., Laupacis A., et al. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995, 155:469-473.
5. Stewart S., Hart C.L., Hole D.J., et al. Apopulation-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002, 113:359-364.
6. Bunch T.J., Weiss J.P., Crandall B.G., et al. Atrial fibrillation is independently associated with senile, vascular, and alzheimer's dementia. Heart Rhythm 2010, 7:433-437.
7. Magnani J.W., Rienstra M., Lin H., et al. Atrial fibrillation: current knowledge and future directions in epidemiology and genomics. Circulation 2011, 124:1982-1993.
8. Calkins H., Kuck K.H., Cappato R., et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace 2012, 14:528-606.
9. Haissaguerre M., Jais P., Shah D.C., et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. NEngl J Med 1998, 339:659-666.
10. Cappato R., Calkins H., Chen S.A., et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol 2010, 3:32-38.
11. Pinho-Gomes A.C., Reilly S., Brandes R.P., et al. Targeting inflammation and oxidative stress in atrial fibrillation: role of 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibition with statins. Antioxid Redox Signal 2014, 20:1268-1285.
12. Corradi D. Atrial fibrillation from the pathologist's perspective. Cardiovasc Pathol 2014, 23:71-84.
13. Nattel S., Harada M. Atrial remodeling and atrial fibrillation: recent advances and translational perspectives. JAm Coll Cardiol 2014, 63:2335-2345.
14. Menezes A.R., Lavie C.J., DiNicolantonio J.J., et al. Atrial fibrillation in the 21st century: a current understanding of risk factors and primary prevention strategies. Mayo Clin Proc 2013, 88:394-409.
15. Wijffels M.C., Kirchhof C.J., Dorland R., et al. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995, 92:1954-1968.
16. Workman A.J., Kane K.A., Rankin A.C. The contribution of ionic currents to changes in refractoriness of human atrial myocytes associated with chronic atrial fibrillation. Cardiovasc Res 2001, 52:226-235.
17. Ausma J., Wijffels M., Thone F., et al. Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat. Circulation 1997, 96:3157-3163.
18. Van Wagoner D.R., Pond A.L., Lamorgese M., et al. Atrial l-type Ca2+ currents and human atrial fibrillation. Circ Res 1999, 85:428-436.
19. Voigt N., Trausch A., Knaut M., et al. Left-to-right atrial inward rectifier potassium current gradients in patients with paroxysmal versus chronic atrial fibrillation. Circ Arrhythm Electrophysiol 2010, 3:472-480.
20. Caballero R., de la Fuente M.G., Gomez R., et al. In humans, chronic atrial fibrillation decreases the transient outward current and ultrarapid component of the delayed rectifier current differentially on each atria and increases the slow component of the delayed rectifier current in both. JAm Coll Cardiol 2010, 55:2346-2354.
21. Filgueiras-Rama D., Price N.F., Martins R.P., et al. Long-term frequency gradients during persistent atrial fibrillation in sheep are associated with stable sources in the left atrium. Circ Arrhythm Electrophysiol 2012, 5:1160-1167.
22. He X., Gao X., Peng L., et al. Atrial fibrillation induces myocardial fibrosis through angiotensin II type 1 receptor-specific arkadia-mediated downregulation of SMAD7. Circ Res 2011, 108:164-175.
23. Kaur K., Zarzoso M., Ponce-Balbuena D., et al. TGF-beta1, released by myofibroblasts, differentially regulates transcription and function of sodium and potassium channels in adult rat ventricular myocytes. PLoS One 2013, 8:e55391.
24. Yamazaki M., Mironov S., Taravant C., et al. Heterogeneous atrial wall thickness and stretch promote scroll waves anchoring during atrial fibrillation. Cardiovasc Res 2012, 94:48-57.
25. Martins R.P., Kaur K., Hwang E., et al. Dominant frequency increase rate predicts transition from paroxysmal to long-term persistent atrial fibrillation. Circulation 2014, 129:1472-1482.
26. Kong P., Christia P., Frangogiannis N.G. The pathogenesis of cardiac fibrosis. Cell Mol Life Sci 2014, 71:549-574.
27. Musa H., Kaur K., O'Connell R., et al. Inhibition of platelet-derived growth factor-AB signaling prevents electromechanical remodeling of adult atrial myocytes that contact myofibroblasts. Heart Rhythm 2013, 10:1044-1051.
28. Youn J.Y., Zhang J., Zhang Y., et al. Oxidative stress in atrial fibrillation: an emerging role of nadph oxidase. JMol Cell Cardiol 2013, 62:72-79.
29. Elahi M.M., Flatman S., Matata B.M. Tracing the origins of postoperative atrial fibrillation: the concept of oxidative stress-mediated myocardial injury phenomenon. Eur J Cardiovasc Prev Rehabil 2008, 15:735-741.
30. Sag C.M., Wagner S., Maier L.S. Role of oxidants on calcium and sodium movement in healthy and diseased cardiac myocytes. Free Radic Biol Med 2013, 63:338-349.
31. Chang J.P., Chen M.C., Liu W.H., et al. Atrial myocardial NOX2 containing nadph oxidase activity contribution to oxidative stress in mitral regurgitation: potential mechanism for atrial remodeling. Cardiovasc Pathol 2011, 20:99-106.
32. Kim Y.M., Guzik T.J., Zhang Y.H., et al. Amyocardial NOX2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation. Circ Res 2005, 97:629-636.
33. Kim Y.M., Kattach H., Ratnatunga C., et al. Association of atrial nicotinamide adenine dinucleotide phosphate oxidase activity with the development of atrial fibrillation after cardiac surgery. JAm Coll Cardiol 2008, 51:68-74.
34. Zhang J., Youn J.Y., Kim A.Y., et al. Nox4-dependent hydrogen peroxide overproduction in human atrial fibrillation and hl-1 atrial cells: relationship to hypertension. Front Physiol 2012, 3:140.
35. Neuman R.B., Bloom H.L., Shukrullah I., et al. Oxidative stress markers are associated with persistent atrial fibrillation. Clin Chem 2007, 53:1652-1657.
36. Antoniades C., Bakogiannis C., Tousoulis D., et al. Preoperative atorvastatin treatment in cabg patients rapidly improves vein graft redox state by inhibition of Rac1 and NADPH-oxidase activity. Circulation 2010, 122:S66-S73.
37. Mihm M.J., Yu F., Carnes C.A., et al. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 2001, 104:174-180.
38. Carnes C.A., Chung M.K., Nakayama T., et al. Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. Circ Res 2001, 89:E32-E38.
39. Ozaydin M., Peker O., Erdogan D., et al. N-acetylcysteine for the prevention of postoperative atrial fibrillation: a prospective, randomized, placebo-controlled pilot study. Eur Heart J 2008, 29:625-631.
40. Rodrigo R., Vinay J., Castillo R., et al. Use of vitamins C and E as a prophylactic therapy to prevent postoperative atrial fibrillation. Int J Cardiol 2010, 138:221-228.
41. Korantzopoulos P., Kolettis T.M., Kountouris E., et al. Oral vitamin c administration reduces early recurrence rates after electrical cardioversion of persistent atrial fibrillation and attenuates associated inflammation. Int J Cardiol 2005, 102:321-326.
42. Friedrichs K., Klinke A., Baldus S. Inflammatory pathways underlying atrial fibrillation. Trends Mol Med 2011, 17:556-563.
43. Klein W.W. Arrhythmias in inflammatory heart disease (author's transl). Wien Klin Wochenschr 1975, 87:465-468. [in German].
44. Aviles R.J., Martin D.O., Apperson-Hansen C., et al. Inflammation as a risk factor for atrial fibrillation. Circulation 2003, 108:3006-3010.
45. Loricchio M.L., Cianfrocca C., Pasceri V., et al. Relation of C-reactive protein to long-term risk of recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol 2007, 99:1421-1424.
46. Guo Y., Lip G.Y., Apostolakis S. Inflammation in atrial fibrillation. JAm Coll Cardiol 2012, 60:2263-2270.
47. Rizos I., Rigopoulos A.G., Kalogeropoulos A.S., et al. Hypertension and paroxysmal atrial fibrillation: a novel predictive role of high sensitivity C-reactive protein in cardioversion and long-term recurrence. JHum Hypertens 2010, 24:447-457.
48. Chung M.K., Martin D.O., Sprecher D., et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001, 104:2886-2891.
49. Pellegrino P.L., Brunetti N.D., De Gennaro L., et al. Inflammatory activation in an unselected population of subjects with atrial fibrillation: links with structural heart disease, atrial remodeling and recent onset. Intern Emerg Med 2013, 8:123-128.
50. Marcus G.M., Smith L.M., Ordovas K., et al. Intracardiac and extracardiac markers of inflammation during atrial fibrillation. Heart Rhythm 2010, 7:149-154.
51. Mentz R.J., Bakris G.L., Waeber B., et al. The past, present and future of renin-angiotensin aldosterone system inhibition. Int J Cardiol 2013, 167:1677-1687.
52. Iravanian S., Dudley S.C. The renin-angiotensin-aldosterone system (RAAS) and cardiac arrhythmias. Heart Rhythm 2008, 5:S12-S17.
53. Ito Y., Yamasaki H., Naruse Y., et al. Effect of eplerenone on maintenance of sinus rhythm after catheter ablation in patients with long-standing persistent atrial fibrillation. Am J Cardiol 2013, 111:1012-1018.
54. Kimura S., Ito M., Tomita M., et al. Role of mineralocorticoid receptor on atrial structural remodeling and inducibility of atrial fibrillation in hypertensive rats. Hypertens Res 2011, 34:584-591.
55. Iraqi W., Rossignol P., Angioi M., et al. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS) study. Circulation 2009, 119:2471-2479.
56. Pitt B., Stier C.T., Rajagopalan S. Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease. JRenin Angiotensin Aldosterone Syst 2003, 4:164-168.
57. Burstein B., Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. JAm Coll Cardiol 2008, 51:802-809.
58. Ehrlich J.R., Hohnloser S.H., Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J 2006, 27:512-518.
59. Chen C.L., Huang S.K., Lin J.L., et al. Upregulation of matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases in rapid atrial pacing-induced atrial fibrillation. JMol Cell Cardiol 2008, 45:742-753.
60. Frangogiannis N.G., Michael L.H., Entman M.L. Myofibroblasts in reperfused myocardial infarcts express the embryonic form of smooth muscle myosin heavy chain (smemb). Cardiovasc Res 2000, 48:89-100.
61. Verheule S., Sato T., Everett T., et al. Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta1. Circ Res 2004, 94:1458-1465.
62. Rahmutula D., Marcus G.M., Wilson E.E., et al. Molecular basis of selective atrial fibrosis due to overexpression of transforming growth factor-beta1. Cardiovasc Res 2013, 99:769-779.
63. Dixon I.M. The soluble interleukin 6 receptor takes its place in the pantheon of interleukin 6 signaling proteins: phenoconversion of cardiac fibroblasts to myofibroblasts. Hypertension 2010, 56:193-195.
64. Santiago J.J., Dangerfield A.L., Rattan S.G., et al. Cardiac fibroblast to myofibroblast differentiation invivo and invitro: expression of focal adhesion components in neonatal and adult rat ventricular myofibroblasts. Dev Dyn 2010, 239:1573-1584.
65. Dobaczewski M., Bujak M., Zymek P., et al. Extracellular matrix remodeling in canine and mouse myocardial infarcts. Cell Tissue Res 2006, 324:475-488.
66. Espira L., Czubryt M.P. Emerging concepts in cardiac matrix biology. Can J Physiol Pharmacol 2009, 87:996-1008.
67. Dobaczewski M., Bujak M., Li N., et al. SMAD3 signaling critically regulates fibroblast phenotype and function in healing myocardial infarction. Circ Res 2010, 107:418-428.
68. Thum T., Gross C., Fiedler J., et al. Microrna-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008, 456:980-984.
69. Cleutjens J.P., Verluyten M.J., Smiths J.F., et al. Collagen remodeling after myocardial infarction in the rat heart. Am J Pathol 1995, 147:325-338.
70. Kakkar R., Lee R.T. Intramyocardial fibroblast myocyte communication. Circ Res 2010, 106:47-57.
71. Souders C.A., Bowers S.L., Baudino T.A. Cardiac fibroblast: the renaissance cell. Circ Res 2009, 105:1164-1176.
72. Banerjee I., Fuseler J., Souders C.A., et al. The role of interleukin-6 in the formation of the coronary vasculature. Microsc Microanal 2009, 15:415-421.
73. Zhao W., Zhao T., Huang V., et al. Platelet-derived growth factor involvement in myocardial remodeling following infarction. JMol Cell Cardiol 2011, 51:830-838.
74. Ivarsson M., McWhirter A., Borg T.K., et al. Type i collagen synthesis in cultured human fibroblasts: regulation by cell spreading, platelet-derived growth factor and interactions with collagen fibers. Matrix Biol 1998, 16:409-425.
75. Gaborit N., Steenman M., Lamirault G., et al. Human atrial ion channel and transporter subunit gene-expression remodeling associated with valvular heart disease and atrial fibrillation. Circulation 2005, 112:471-481.
76. Lau D.H., Psaltis P.J., Mackenzie L., et al. Atrial remodeling in an ovine model of anthracycline-induced nonischemic cardiomyopathy: remodeling of the same sort. JCardiovasc Electrophysiol 2011, 22:175-182.
77. Barondes S.H., Castronovo V., Cooper D.N., et al. Galectins: a family of animal beta-galactoside-binding lectins. Cell 1994, 76:597-598.
78. de Boer R.A., Yu L., van Veldhuisen D.J. Galectin-3 in cardiac remodeling and heart failure. Curr Heart Fail Rep 2010, 7:1-8.
79. Henderson N.C., Mackinnon A.C., Farnworth S.L., et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci U S A 2006, 103:5060-5065.
80. Henderson N.C., Mackinnon A.C., Farnworth S.L., et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol 2008, 172:288-298.
81. Mackinnon A.C., Gibbons M.A., Farnworth S.L., et al. Regulation of tgf-beta1 driven lung fibrosis by galectin-3. Am J Respir Crit Care Med 2012, 185:537-546.
82. Hsu D.K., Dowling C.A., Jeng K.C., et al. Galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma. Int J Cancer 1999, 81:519-526.
83. Nishi Y., Sano H., Kawashima T., et al. Role of galectin-3 in human pulmonary fibrosis. Allergol Int 2007, 56:57-65.
84. Wang L., Friess H., Zhu Z., et al. Galectin-1 and galectin-3 in chronic pancreatitis. Lab Invest 2000, 80:1233-1241.
85. Sasaki S., Bao Q., Hughes R.C. Galectin-3 modulates rat mesangial cell proliferation and matrix synthesis during experimental glomerulonephritis induced by anti-thy1.1 antibodies. JPathol 1999, 187:481-489.
86. Liu Y.H., D'Ambrosio M., Liao T.D., et al. N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. Am J Physiol Heart Circ Physiol 2009, 296:H404-H412.
87. Lopez-Andres N., Rossignol P., Iraqi W., et al. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the care-hf (cardiac resynchronization in heart failure) trial. Eur J Heart Fail 2012, 14:74-81.
88. Liu F.T. Molecular biology of ige-binding protein, ige-binding factors, and ige receptors. Crit Rev Immunol 1990, 10:289-306.
89. Bonniaud P., Margetts P.J., Ask K., et al. Tgf-beta and smad3 signaling link inflammation to chronic fibrogenesis. JImmunol 2005, 175:5390-5395.
90. Li D., Fareh S., Leung T.K., et al. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation 1999, 100:87-95.
91. Yu L., Ruifrok W.P., Meissner M., et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail 2013, 6:107-117.
92. Sonmez O., Ertem F.U., Vatankulu M.A., et al. Novel fibro-inflammation markers in assessing left atrial remodeling in non-valvular atrial fibrillation. Med Sci Monit 2014, 20:463-470.
93. Ho J.E., Yin X., Levy D., et al. Galectin 3 and incident atrial fibrillation in the community. Am Heart J 2014, 167:729-734.e1.
94. Schmutz M., Beer-Borst S., Meiltz A., et al. Low prevalence of atrial fibrillation in asymptomatic adults in geneva, switzerland. Europace 2010, 12:475-481.
95. Heeringa J. Atrial fibrillation: is the prevalence rising?. Europace 2010, 12:451-452.
96. Tellez-Sanz R., Garcia-Fuentes L., Vargas-Berenguel A. Human galectin-3 selective and high affinity inhibitors. Present state and future perspectives. Curr Med Chem 2013, 20:2979-2990.